📌 Conclusion: The new Atezolizumab–Bevacizumab–Cluster (A-B-C) classification captures biological + prognostic heterogeneity in unresectable HCC. A tool to refine trial design, enrich populations, and personalize treatments.
Outcomes were strikingly distinct:
🔹 A had best OS (median not reached), lowest progression (25%), longest PFS (~11 mo).
🔸 B OS ~18 mo
🔸 C OS ~14 mo
Patterns held across BCLC stages + early hepatic decompensation risk.
Tumor biology differed: Cluster C showed poorer differentiation and more macrotrabecular-massive subtype → consistent with aggressive disease biology.
Three clusters emerged:
🔹 A (47.5%) – older, higher BMI, good liver function, multiple small tumors.
🔹 B (11%) – VP1/2 PVI, more HBV, fewer metabolic features.
🔹 C (41.2%) – worse liver function, high AFP, VP3/4 PVI or large tumor burden.
1) We recently published a multicentric study in
cghjournal.org/article/S154...
We analyzed using machine learning an international cohort of 1,399 pts treated for HCC with atezo/bev across 12 centers to uncover clinically meaningful subgroups. @etrepo.bsky.social
6) Immunohistochemistry: PCT is positive in 77% of FLC, but absent in other primary or secondary liver tumors.
In conclusion
👉 serum and tumor PCT = sensitive & specific biomarker for fibrolamellar hepatocellular carcinoma.
5) CALCA (the PCT gene) is strongly overexpressed in FLC and spatial transcriptomics localizes CALCA to tumor cells.
4) In 4 FLC patients, PCT tracked RECIST response under systemic treatment: ↓ in partial response, ↑ in progression, ↔ in stable disease. A promising dynamic monitoring marker.
3) Serum PCT is markedly elevated in FLC vs HCC, CCA or cirrhosis, in both EU & US cohorts.
👉 83% high PCT in FLC vs 0 to 3% in HCC or CCA.
2) Fibrolamellar carcinoma (FLC) affects young patients and lacks reliable biomarkers (AFP/CA19-9 usually normal). An unexpectedly high PCT level in one case led us to investigate PCT across two cohorts (Europe and USA)
1) We recently identified as serum tumor biomarker of fibrolamellar carcinoma, procalcitonin, with @zucmanrossi.bsky.social and @markyarchoan.bsky.social that you can find in www.medrxiv.org/content/10.1...
Claudia Campani from Cordeliers Research Center received Best clinical poster award in @ILCAnews meeting in Hong Kong
Claudia Campani presenting our work on Molecular based therapy in primary liver cancer refractory to systemic treatments in ILCA meeting in Hong Kong
Our work about « Molecular based targeted therapies in primary liver cancers » presented by Claudia Campani at ESMO precision medicine @myesmo.bsky.social
Iron Maiden, Paris 2025
Kendrick Lamar/SZA Paris 2025
Neil Young, Paris 2025
📢ONLINE @natgenet.nature.com
📰Cytidine diphosphate diacylglycerol synthase 2 is a synthetic lethal target in mesenchymal-like cancers.
By Tim Arnoldus, Daniel S. Peeper and colleagues.
⬇️
www.nature.com/articles/s41...
Joe Satriani and Steve Vaï, Paris 2025
Pr Éric Trepo on genetic prédisposition to HCC on alcohol related liver Disease in the Paris Liver Cancer Group Day, June 2025
Paris Liver Cancer Group day, 19 June 2025.
Paris Liver Cancer Group day, 19 June 2025.
Yes sure !
7/ In conclusion,
Systematic biopsies during RFA = safe + informative.
They can sharpen diagnosis, guide therapy & predict prognosis in newly diagnosed HCC. #HCC #LiverCancer #Biopsy
6/
🧾 Non-tumor biopsy insights
82% showed histological cirrhosis, but 15% had discrepancies with tumor board diagnosis—underlining the clinical relevance of liver biopsies beyond the tumor.
5/
🧬 Biopsy for molecular analysis
Samples with >25% tumor cells enabled transcriptomic analysis, validating their use for future molecular profiling and personalized treatment strategies.
4/
⚠️ Prognostic implications
Biopsy uncovered 3% cholangiocarcinoma/hepatocholangiocarcinoma—linked to significantly shorter survival.
Also, macrotrabecular-massive HCC subtype had higher recurrence (P=0.037).
3/
🔬 Diagnostic value
Tumor biopsy confirmed HCC in 66% of cases. Diagnostic yield was better with:
✔️ Larger nodules
✔️ Peripheral location
✔️ Good ultrasound visibility
34% were non-diagnostic, 5% differed from prior board diagnosis (hepatocholangiocarcinoma, cholangiocarcinoma, dysplastic nodules)
2/We looked in 248 patients at safety, diagnostic yield & prognostic insights from tumor + non-tumor biopsies.
✅ Safety first
Biopsies done during RFA had a low complication rate:
🔹 Bleeding in only 1.9% of cases
🔹 No biopsy-related deaths
